Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002). Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001). Feedback from patients participating in the International Myeloma Foundation, patient programs. These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. 'Consensus' reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into: 1. Diagnostic criteria. 2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies.
Durie
Brian G M
BG
Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA. bdurie@salick.com
Kyle
Robert A
RA
Belch
Andrew
A
Bensinger
William
W
Blade
Joan
J
Boccadoro
Mario
M
Child
J Anthony
JA
Comenzo
Raymond
R
Djulbegovic
Ben
B
Fantl
Dorotea
D
Gahrton
Gosta
G
Harousseau
Jean Luc
JL
Hungria
Vania
V
Joshua
Douglas
D
Ludwig
Heinz
H
Mehta
Jayesh
J
Morales
Angelina Rodrique
AR
Morgan
Gareth
G
Nouel
Amara
A
Oken
Martin
M
Powles
Raymond
R
Roodman
David
D
San Miguel
Jesus
J
Shimizu
Kazuyuki
K
Singhal
Seema
S
Sirohi
Bhawna
B
Sonneveld
Pieter
P
Tricot
Guido
G
Van Ness
Brian
B
D000740:Anemia / Q000209:etiology / Q000628:therapy; D000970:Antineoplastic Agents / Q000592:standards / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards / Q000627:therapeutic use; D001847:Bone Diseases / Q000209:etiology / Q000628:therapy; D003937:Diagnosis, Differential; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000628:therapy; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D011785:Quality Assurance, Health Care; D033581:Stem Cell Transplantation / Q000592:standards; D016019:Survival Analysis
D000970:Antineoplastic Agents